4D Molecular Therapeutics, Inc.
News
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
Business Wire The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (4D Molecular Therapeutics or...\n more…
4D Molecular Therapeutics (NASDAQ:FDMT) Rating Reiterated by Cantor Fitzgerald
Ticker Report 4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)s stock had its "overweight" rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued on Monday...\n more…
Wall Street Analysts Think 4D Molecular Therapeutics (FDMT) Could Surge 225.1%: Read This Before Placing a Bet
Zacks Investment Research 4D Molecular Therapeutics, Inc. (FDMT) closed the last trading session at $15.62, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price...\n more…
4DMT Announces Presentations at Upcoming Retina Conferences
Globe Newswire EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...\n more…
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
Globe Newswire EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...\n more…